Competitor Analysis: CXCR4 Antagonists for Modulation of the Tumor Microenvironment
Competitor Analysis: CXCR4 Antagonists for Modulation of the Tumor Microenvironment
This industry report describes the competitive R&D landscape of novel antagonists of the C-X-C chemokine receptor type 4 (CXCR4) and inhibitors of its ligand CXCL12 (SDF-1) for modulation of the immunosuppressive tumor microenvironment as of December 2016. The Competitor Analysis includes antagonists of CXCR4 based on small molecules, peptides and antibodies as well as inhibitors of CXCL12, the ligand for CXCR4. Included are molecules being studied as single agent as well as in combination trials.
Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of CXCR4 antagonists for modulation of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of CXCR4 Antagonists. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This industry report describes the competitive R&D landscape of novel antagonists of the C-X-C chemokine receptor type 4 (CXCR4) and inhibitors of its ligand CXCL12 (SDF-1) for modulation of the immunosuppressive tumor microenvironment as of December 2016. The Competitor Analysis includes antagonists of CXCR4 based on small molecules, peptides and antibodies as well as inhibitors of CXCL12, the ligand for CXCR4. Included are molecules being studied as single agent as well as in combination trials.
Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of CXCR4 antagonists for modulation of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of CXCR4 Antagonists. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) CHEMOKINE RECEPTOR TYPE 4 (CXCR4) ANTAGONISTS & CXCL12 INHIBITORS
Small Molecule-Based CXCR4 Antagonists
Peptide-Based CXCR4 Antagonists
Antibody-Based CXCR4 Antagonists
2) CXCL12 INHIBITORS
3) CORPORATE CXCR4 ANTAGONIST R&D PIPELINES
Small Molecule-Based CXCR4 Antagonists
Peptide-Based CXCR4 Antagonists
Antibody-Based CXCR4 Antagonists
2) CXCL12 INHIBITORS
3) CORPORATE CXCR4 ANTAGONIST R&D PIPELINES
More Publications
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?/R, CXCR4, CSF-1R, CD47-SIRP?, Adenosine, STING & Others
US$ 1,283.00
December 2016
117 pages
Competitor Analysis: Interleukin-17/Receptor (IL-17/R) Antagonists
US$ 170.00
August 2015
20 pages
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology
US$ 2,310.00
December 2016
319 pages
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family
US$ 225.00
January 2016
28 pages
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
US$ 350.00
April 2016
74 pages
